<< Back to News

System Formulary Update
Nivolumab/Relatlimab (Opdualag)

Situation

Nivolumab/Relatlimab (Opdualag) 240 mg nivolumab/80 mg relatlimab (20 mL SDV) for injection was approved for addition to the health system formulary at the August 2022 System Pharmacy and Therapeutics Committee meeting.

Background

The following medication was reviewed: Nivolumab/Relatlimab (Opdualag) 240 mg nivolumab/80 mg relatlimab (20 mL SDV) for injection

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Nivolumab/Relatlimab (Opdualag) 240 mg nivolumab/80 mg relatlimab (20 mL SDV) for injection

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic changes will Go-Live on Tuesday, September 27, 2022.